Effects of Octanoic Acid for Treatment of Essential Voice Tremor
NCT01864525 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 17
Last updated 2018-08-20
Summary
Essential voice tremor is a neurological condition that produces a regular, shaking quality in the voice. One form of drug treatment that produces some improvement in tremor of the hands is octanoic acid, which is a food additive that is similar to alcohol. Research suggests that octanoic acid may reduce tremor in the hands/arms with few side effects and no intoxication effects. This study will determine whether octanoic acid may be useful for reducing tremor when it affects the voice. Researchers are hypothesizing that octanoic acid will reduce the effects of tremor on the voice.
Conditions
- Essential Voice Tremor
- Vocal Tremor
- Voice Tremor
- Essential Tremor of Voice
Interventions
- DRUG
-
Octanoic acid
- DRUG
-
Inactive capsule
Sponsors & Collaborators
-
National Institute on Deafness and Other Communication Disorders (NIDCD)
collaborator NIH -
Syracuse University
lead OTHER
Principal Investigators
-
Soren Y Lowell, PhD · Syracuse University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 21 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-07-31
- Primary Completion
- 2016-12-22
- Completion
- 2017-03-31
Countries
- United States
Study Locations
More Related Trials
-
Novel Therapies for Essential Tremor
NCT00018564 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study to Evaluate CAD-1883 in Essential Tremor
NCT03688685 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy, Safety, and Pharmacokinetics of ES-481 in Adult Patients With Essential Tremors
NCT05234762 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
NCT00021697 ·Status: COMPLETED ·Phase: PHASE3
-
Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor
NCT00598078 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering
NCT01684657 ·Status: SUSPENDED ·Phase: PHASE3
-
Nicergoline Use in Dysphagia Patients
NCT05551182 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 2 RCT Study of CX-8998 for Essential Tremor
NCT03101241 ·Status: COMPLETED ·Phase: PHASE2
-
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel Disorders
NCT00004802 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Nuedexta on Bulbar Physiology and Function in ALS
NCT03883581 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Clinical Trial of PRAX-944 in Participants With Essential Tremor
NCT05021978 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Oral Treatment MTR-601 in Cervical Dystonia
NCT06830642 ·Status: SUSPENDED ·Phase: PHASE2
-
The Efficacy of Aldehyde Dehydrogenase Enzyme in Essential Tremor Patients: A Single-Center Study
NCT07238725 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)
NCT04492956 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia
NCT03214588 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Breathing Pattern and Dyspnea in Subjects With Tetraplegia
NCT00904436 ·Status: COMPLETED ·Phase: NA
-
Upper Limb Tremor Reduction in Essential Tremor Patients
NCT06343285 ·Status: COMPLETED ·Phase: NA
-
An Open-label Study of the Effects of Acetyl-L-Carnitine on Cardiovascular Outcomes in Friedreich's Ataxia
NCT01921868 ·Status: UNKNOWN ·Phase: NA
-
Clinical Trial Nuedexta in Subjects With ALS
NCT01806857 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Topical Apraclonidine for the Treatment of Ocular Synkinesis
NCT05167760 ·Status: WITHDRAWN ·Phase: PHASE4
-
A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor
NCT05021991 ·Status: COMPLETED ·Phase: PHASE2
-
4-Aminopyridine in Episodic Ataxia Type 2
NCT01543750 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor
NCT04305275 ·Status: COMPLETED ·Phase: PHASE2
-
Hyperkinetic Movements in Patients With Disease of Motor Neurons and Their Response to Treatment With Nusinersen
NCT04825119 ·Status: UNKNOWN
-
Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients
NCT02770807 ·Status: COMPLETED ·Phase: PHASE3